Legend Biotech has named Ingrid Zhang, a 15-year Novartis veteran, as its permanent CEO. Both Fierce Pharma and Fierce Biotech report the appointment, describing the CAR-T specialist as looking toward its next phase of growth.
Zhang's background is in commercial operations, which aligns with the company's push to boost commercial potential. The two reports agree on her credentials and the strategic intent behind the hire.
The reports differ slightly in context. Fierce Biotech notes that Zhang replaces Ying Huang, who left suddenly in July; Fierce Pharma's piece does not mention Huang's departure. That context matters for understanding the leadership transition.